Analyst Josh Jennings from TD Cowen maintained a Buy rating on Vericel (VCEL – Research Report) and decreased the price target to $55.00 from $72.00.
Josh Jennings has given his Buy rating due to a combination of factors, including Vericel’s ability to meet its revenue guidance despite challenges in its Burn Care unit. The company’s MACI product demonstrated strong performance, contributing significantly to the quarterly revenue and showing notable growth compared to the previous year.
Jennings also highlights the potential for future growth, particularly in the second half of 2025, driven by an expanding sales force and contributions from the Arthro segment. Additionally, Vericel’s solid cash position and lack of debt provide a stable financial foundation, supporting the company’s growth prospects and justifying the Buy rating.
According to TipRanks, Jennings is a 4-star analyst with an average return of 2.2% and a 50.10% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Establishment Labs Holdings, and Edwards Lifesciences.